HIV impairs TNF-alpha release in response to Toll-like receptor 4 stimulation in human macrophages in vitro

Souvenir D Tachado1, Jianmin Zhang, Jinping Zhu

  • 1Department of Pulmonary, Critical Care and Sleep Medicine, Kirstein Hall, Room E/KSB-23, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

Insights

HIV impairs the innate immune response to bacterial pneumonia by reducing Toll-like receptor 4 (TLR4)-mediated TNF-alpha release in macrophages. This involves altered extracellular regulated kinase (ERK)1/2 signaling, potentially treatable by inhibiting phosphatases.

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • Increased bacterial pneumonia risk in HIV+ individuals suggests impaired innate immunity.
  • Toll-like receptor (TLR) signaling is crucial for host defense against bacterial pathogens.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying impaired TLR4-mediated immune responses in HIV+ macrophages.
  • To investigate the role of HIV proteins and cellular signaling pathways in this impairment.

Main Methods:

  • Stimulation of U937 and U1 macrophage cell lines with lipid A (TLR4 ligand).
  • Analysis of TNF-alpha release, ERK1/2 and MEK1/2 phosphorylation, and MAP kinase phosphatase-1 (MKP-1) expression.
  • Assessment of HIV nef protein effects and impact of phosphatase inhibition/MKP-1 gene silencing.
  • Validation in primary human alveolar macrophages from healthy and HIV+ donors.

Main Results:

  • HIV+ U1 macrophages exhibited reduced TNF-alpha release and ERK1/2 phosphorylation upon TLR4 stimulation compared to healthy U937 cells.
  • Reduced ERK1/2 phosphorylation in HIV+ cells was linked to increased MKP-1, not upstream MEK1/2 inhibition.
  • HIV nef protein induced MKP-1 and reduced TNF-alpha release in healthy macrophages.
  • Inhibition of phosphatases or MKP-1 silencing partially restored TLR4-mediated TNF-alpha release in HIV+ macrophages.

Conclusions:

  • HIV alters macrophage TLR4 signaling, specifically through ERK1/2 pathway dysregulation mediated by MKP-1, impairing innate immune response to bacteria.
  • Targeting cellular phosphatases represents a potential therapeutic strategy for bacterial pneumonia in HIV+ individuals.